Mankind Pharma Ltd has posted a 21 percent year-on-year decline in its consolidated profit after tax (PAT) to Rs 520 crore for the quarter ended September 30, 2025.

The drug major had posted a PAT of Rs 661 crore in the same quarter last year.

Despite the profit dip, the company’s revenue from operations rose to Rs 3,697 crore during the July–September period. “ Mankind ’s revenue increased by 20.8% supported by outperformance in Chronic and BSV consolidation, partially impacted by GST disruption. While chronic continued an outperformance led by 1.3x and 1.2x in Cardiac and Anti- diabetes respectively, OTC was impacted due to heavy rains along with GST 2.0 and we expect growth recovery in H2," Rajeev Juneja, Vice Chairman & Managing Director of the company stated. "BSV growth i

See Full Page